Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Eicosapentaenoic Acid (EPA) is an omega-3 polyunsaturated fatty acid primarily found in fish oil. There is some scientific interest in the potential role of EPA in supporting bone health and mitigating osteoporosis, largely due to its anti-inflammatory properties and its influence on bone metabolism. Preclinical studies have shown that omega-3 fatty acids, including EPA, may decrease bone resorption by modulating cytokine production and reducing inflammation, both of which are factors in the development and progression of osteoporosis. Some animal studies suggest that diets rich in EPA can increase bone mineral density and improve bone strength. However, evidence from human clinical trials remains limited and inconclusive. A few small-scale studies and meta-analyses indicate that omega-3 supplementation might benefit bone turnover markers or bone mineral density, but results are inconsistent and often confounded by the inclusion of other nutrients (such as vitamin D and calcium) alongside EPA. At present, there is not enough robust, high-quality clinical evidence to recommend EPA as a primary or adjunctive therapy for osteoporosis treatment or prevention. The current consensus in the scientific community is that while EPA may have a theoretical and mechanistic basis for supporting bone health, more large-scale, rigorous human trials are required to validate its efficacy for osteoporosis.

More about eicosapentaenoic acid
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by eicosapentaenoic acid

Products containing eicosapentaenoic acid